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4 Indole-based ligands as potential 5-HT7 receptor agonists 
 
4.1 Introduction 
Previous studies on the characterization of the pharmacophore for 5-HT7 receptor agonism, 
as described in Chapter 3, suggested a limited steric freedom with respect to the basic skeleton of 
potential new agonists. Unlike the indication obtained from the initial molecular modeling studies 
that THIQ-based ligands might be interesting candidates as novel 5-HT7 receptor agonists, binding 
data demonstrated that this class of compounds has no affinity for this receptor subtype. As a 
result, it was hypothesized that ligands might experience considerable steric repulsions of amino 
acid residues at the binding site of the receptor if they have to adopt a non-equiplanar orientation 
as compared to the ligands used to derive the initial pharmacophore model. Similarly, ligands that 
possess atoms and/or substituents which are oriented out of this plane might also show substantial 
lower affinity for the binding site of the receptor. 
Among the 5-HT7 receptor agonists that were used to determine the pharmacophore model 
for this receptor subtype was a considerable number of tryptamine-based ligands. The presumed 
active conformation of these highly flexible tryptamines could be deduced from the rigid ergoline 









Figure 4.1: Chemical structure of (+)-LSD. Tryptamine group emphasized with thick lines. 
 
Because of the perfectly flat character of the aromatic heterocyclic ring structure of the 
indole nucleus, along with the greater synthetic accessibility of tryptamines compared to ergolines, 
it seemed likely that tryptamines could provide us with valuable information for the present 
pharmacophore model and future computational models (e.g. Comparative Molecular Field 
Analysis, CoMFA), and help to extend the knowledge of the SAR of this class of compounds. In 
addition, the effect of introducing (small) substituents to the core of the indole-based ligands on the 
binding affinity could disclose the capacity of the binding site of the receptor to host these (small) 
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substituents, while the rest of the molecule complies with the prerequisites of the pharmacophore 
model (i.e. the flat aromatic ring structure).  
 
4.1.1 5-Methoxy-tryptamines 
From the initial pharmacophore-identifying procedure described in Chapter 2, it was 
concluded that the substituent at the 5-position of indole-based ligands should be hydrogen bond 
accepting. Apart from 6-methoxy-tryptamine and tryptamine – two fairly binding ligands lacking a 
hydrogen bond accepting group at the 5-position – all indole ligands possess a substituent at this 
position capable of forming a hydrogen bond. Moreover, there is no significant loss of receptor 
affinity when the 5-hydroxyl group is disposed of its hydrogen bond donating capacity by alkylation 
of this substituent (compare affinities of 5-HT and 5-MeOT). Hence, a series of 5-methoxy-
tryptamines was synthesized with a variety of substituents at the ethylamine nitrogen and the 
indole nucleus to verify this rationale and study the SAR of this class of ligands. 
 
4.1.2 6-Methoxy-N-ethylamino-indoles 
In line with the rationale to design and synthesize a series of 5-methoxy-tryptamines, it 
should be interesting to investigate the binding affinity of 6-methoxy-indoles and analogues as well. 
As was known from the formulation of the initial pharmacophore model, 6-methoxy-tryptamine 
showed moderate affinity for the 5-HT7 receptor15. However, the importance of the hydrogen bond 
donating NH-group of the indole nucleus was unclear. The high affinity of 1-methyl-5-HT15 
suggested that substitution of this group by a methyl group had no considerable effect on the 
binding affinity. Also, the affinities for the 5-HT7 receptor of (R)-8-OH-DPAT and 1-
naphthylpiperazine, despite the absence of a similar functional group, supported this hypothesis. 
For that reason, the synthesis of 6-substituted indoles with the ethylamine side chain attached to 
the nitrogen of the 5-membered heterocyclic ring of the indole nucleus was considered. As a regio-
isomer (Figure 4.2) of the typical tryptamines, these compounds could offer a valuable contribution 
to the refinement of the initial pharmacophore model and could be used to examine the importance 
of the hydrogen bond donating NH-group of indoles. Additionally, verification of the binding 
properties of the precursors of these target compounds, the indolines, being intermediates in this 
synthesis pathway (see Scheme 4.4), could possibly validate the hypothesis that the aromatic core 
of 5-HT7 receptor agonists is flat.  














Figure 4.2: Indole regio-isomers.  
 
4.1.3 3-Tetrahydro-pyridinyl-indoles 
3-(1,2,5,6-Tetrahydropyridin-4-yl)-indoles (4-THPI) represent a group of semi-rigid 
analogues of tryptamines, possessing the inherent properties of acting on serotonin receptors. As 
a consequence of the amino group being part of the tetrahydropyridine (THP) ring, it offered an 
interesting opportunity to study the difference in binding affinity of this class of compounds with 









Figure 4.3: Basic structure of 5-methoxy-3-(1,2,5,6-tetrahydropyridin-4-yl)-indoles (4-THPI). 
 
Despite the presence of a rotatable bond between the pyridine group and the 3-carbon 
atom of the indole nucleus, this bond is constrained to near-planar conformations as a result of 
conjugation between the indole ring and the double bond of the THP ring. The distance between 
the basic nitrogen of the THP ring and the centroid of the six-membered aromatic ring of the indole 
nucleus is only slightly larger compared to the freely moving ethylamine side chains of tryptamines, 
as can be derived from molecular modeling calculations2 (Table 4.1). Nevertheless, a series of 
ligands based on 4-THPI had shown to bind to the closely related 5-HT1A receptor and 5-HT2 
receptor with moderate to high affinity3. Encouraged by these data, the applicability of 4-THPI as 
5-HT7 receptor ligands was investigated. 
 




4.2.1 Synthesis of 5-methoxytryptamines 
The synthesis of a series of possible 5-HT7 receptor ligands with a hydrogen bond 
accepting group at the 5-position started with either 5-methoxy-indole or 5-methoxy-2-methyl-
indole, as illustrated in Scheme 4.1. By varying the substituents at the ethylamine nitrogen, and by 
introduction of small alkyl substituents at different positions of the indole nucleus, we aimed to 













































5a-6a: R1 = H
5b-6b: R1 = CH3
7-9a: R1, R2, R3 = H
7-9b: R1 = H, R2, R3 = CH3
7-9c: R1 = H, R2, R3 = n-Pr
7-9d: R1 = H, R2, R3 = -(CH2)4-
7-9e: R1 = H, R2, R3 = -(CH2)2O(CH2)2-
7-9f:  R1 = H, R2 = CH3, R3 = Bn
7a-j
7a-j 8a-j 9a-j
7-9g: R1 = CH3, R2, R3 = H
7-9h: R1, R2, R3 = CH3
7-9i:  R1 = CH3, R2, R3 = n-Pr
7-9j:  R1 = CH3, R2, R3 = -(CH2)4-
5a-b 6a-b
 
Scheme 4.1: Synthesis of 5-methoxytryptamines. Reagents and conditions: (a) Oxalyl chloride, diethyl ether. (b) 
Amine, H2O / CHCl3. (c) LiAlH4, THF. (d) KO-t-Bu, dimethyl-oxalate, DMF, reflux. 
 
All ligands within this class of compounds were accessible by introduction of the ethylamine 
side chain through coupling of the indole nucleus with oxalyl chloride13. The oxo-acetyl chloride 
intermediate, which precipitates readily from ether, can subsequently be derivatized with the 
primary or secondary amine of choice to form the oxo-amid. Reduction of the side chain was 
effectuated using an excess of LiAlH4 in refluxing THF. There was no difference observed in 
reactivity when 2-methyl-indole was used as a starting material in this procedure. 
































R2, R3 = CH3
 
Scheme 4.2: Synthesis of N-methylated indole derivatives. Reagents and conditions: (a) KO-t-Bu, dimethyl-oxalate, 
DMF, reflux. (b) Oxalyl chloride, diethyl ether (c) Dimethylamine, H2O / CHCl3. 
 
On the other hand, attempts to synthesize N-methyl derivatives of these compounds, 
starting directly by methylation of 5-methoxy-1H-indole, followed by coupling with oxalyl chloride 
and the appropriate amine, failed at the stage of reduction of the 2-oxo-acetamide group using 
LiAlH4 (Scheme 4.2 and Scheme 4.3). Under these circumstances, intermediates with an 2-oxo-
acetamide group (like 12) could not be converted to the desired products with ethylamine side 
chains. The use of a large excess of reducing agent, elevated temperature, and extended reaction 
times was not helpful, and the reaction stopped at the stage of 2-hydroxy-ethylamine 13 as 
depicted in Scheme 4.3. It is hypothesized that, in case of the unsubstituted NH-indole derivatives, 
the final step in this reduction is facilitated by the formation of an indolyl anion upon dissociation of 
the aluminum oxide complex. In case of the N-methylated indoles, deprotonation of the indole-NH 
is impossible. Therefore, isomerization of an indolyl anion does not occur, and LiAlH4 reduction of 
this carbonyl group stops at the stage of a secondary alcohol. As a consequence, N-methylated 
analogs of 8a-f were obtained through alkylation of the tryptamines in the final step after reduction 
















































































































Scheme 4.3: Differences in reactivity between unsubstituted (top) and N-substituted indole substrates (bottom). 
Reagents and conditions: (a) LiAlH4, THF, reflux. (b) H2O. 
 
4.2.2 Synthesis of 6-methoxy-N-ethylamine-indole ligands 
Due to the considerable reactivity of the 2- and 3-position of the indole nucleus, it seemed 
wise to synthesize the series of 6-methoxy-N-ethylamine-indole ligands via the reduced indole core 
– the indoline or 2,3-dihydro-indole – as illustrated in Scheme 4.4. As stated before, with this 
precursor of the desired 6-methoxy-indole-N-ethylamine, it was possible to study the relevance of 
the flat architecture of the heterocyclic ring system in more detail, as well as the importance of its 
aromatic character. 
6-Methoxy-indole (16) was prepared from 4-methyl-3-nitroanisole (14) via the Batcho-
Leimgruber pathway with dimethylformamide dimethyl acetal in pyrrolidine followed by ring closure, 
which occurs after hydrogenation of the nitro group4,5. To prevent substitution of the 2- and 3-
positions of the indole nucleus during the succeeding steps, the indole was reduced with NaCNBH3 
in glacial acetic acid to indoline 17. Subsequent substitution of the nitrogen atom with an 
ethylamine side chain proceeded via the 2-chloroacetylated intermediate 18. Reduction of the 
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amide group at this stage appeared to be problematic, typically resulting in cleavage of the amide 
bond. Instead of LiAlH4 which resulted in complete cleavage of amide, other reducing agents like 
BH3-dimethylsulphide complex, and AlH3 (prepared from LiAlH4 and H2SO4 or AlCl3) were used. 
The latter giving the best results, although yields remain low in some cases. During the final step, 



































19-21a: R2, R3 = CH3
19-20b: R2, R3 = n-Pr
 
19-20c: R2, R3 = -(CH2)2O(CH2)2-
19-20d: R2, R3 = -(CH2)2NCH3(CH2)2-
 
Scheme 4.4: Synthesis of 6-methoxy-N-ethylamine-indole ligands. Reagents and conditions: (a) Pyrrolidine, 
dimethylformamide dimethyl acetal, DMF, 100 ˚C. (b) Pd/C, H2, ethanol. (c) NaCNBH3, AcOH. (d) 2-
Chloroacetyl chloride, K2CO3, CH2Cl2. (e) Amine, K2CO3, CH3CN. (f) LiAlH4, AlCl3 or H2SO4, THF. (g) 
MnO2, CH3CN, reflux. 
 
4.2.3 Synthesis of 3-tetrahydropyridinylindoles 
A limited number of ligands based on the indole core, again with the hydrogen bond 
accepting group at the 5-position, but with restricted rotational freedom of the ethylamine side 
chain by ‘locking’ it into a THP ring10, was prepared in a simple one step synthesis according to 
Scheme 4.5. Using N-benzyl protected piperidone, this approach offers the possibility to introduce 
different substituents at the tetrahydropyridinyl nitrogen after removal of the protecting group. 












5a 22a: R1 = CH3
22b: R1 = Bn
 
22c: R1 = H b
 
Scheme 4.5: Synthesis of 3-tetrahydro-pyridinyl-indole ligands. Reagents and conditions: (a) Piperidone, NaOCH3, 
CH3OH, reflux. (b) Pd/C, H2, EtOH. 
 
4.3 Pharmacology 
Compounds 8b, 8d, 8g-j, 9b-f, 20a-d, 21a, and 22a-c were evaluated at Pfizer and former 
SmithKline-Beecham laboratories for their ability to compete for [3H]5-CT binding to cloned rat 
5-HT7 receptors expressed in HEK-293 cells. Additionally, the effect on adenylate cyclase activity 
relative to the effects of 5-CT (agonist, 100%) and methiothepin (inverse agonist, 100%) was 
determined at Pfizer laboratories for a selection of these compounds. These results are 
summarized in Table 4.1. 
 
4.4 Results and discussion 
By extending the series of indole-based ligands that were known from literature to interact 
with the 5-HT7 receptor, we aimed to get a more detailed image of the agonist pharmacophore. 
Additionally, association of the pharmacological data obtained with the chemical structures of the 
tested compounds, could help to reveal the characteristics of the binding site of the receptor in 
future molecular modeling computations (3D-QSAR, CoMFA). 
When the pharmacological data were collected, it appeared that the higher binding affinities 
were limited to those tryptamines that lack (small) substituents attached to the indole ring structure. 
For comparison, structural and pharmacological data of the earlier tested ligands serotonin, 5-
methoxytryptamine (5-MeOT), and bufotenin (N,N-dimethyl-5-hydroxytryptamine) are also listed in 
Table 4.1. Substitution of the ethylamine nitrogen with alkyl groups of increasing size results in a 
decrease of 5-HT7 receptor affinity: roughly 25-fold per carbon atom, while calculated1 logP values 
show a less pronounced increase. Nevertheless, despite its decreased receptor affinity, 8b can be 
classified as a full agonist, while 8d is capable of increasing basal adenylate cyclase activity with 
only 39% compared to 5-CT.  
 






























































   2.76 6.02 6.95 1.24 10.18 0.6b n.d. 
5-MeOT 
   2.77 6.00 6.88 1.74 10.18 0.9b n.d. 
Bufotenin 
   2.77 6.03 6.93 2.00 9.24 8b n.d. 
8b H CH3, CH3 H 2.77 6.02 6.91 2.51 9.24 25 +92 
8d H -(CH2)4- H 2.77 6.01 6.89 3.02 9.64 570 +39 
8g CH3 H, H H 2.77 6.02 6.90 1.77 10.18 132 n.d. 
8h CH3 CH3, CH3 H 2.77 6.03 6.91 2.53 9.24 1100c +17 
8i CH3 n-Pr, n-Pr H 2.77 6.02 6.91 4.47 10.43 1500 n.d. 
8j CH3 -(CH2)4- H 2.77 6.02 6.90 3.04 9.64 8400 n.d. 
9b H CH3, CH3 CH3 2.77 6.02 6.91 2.71 9.24 390 -69 
9c H n-Pr, n-Pr CH3 2.77 6.02 6.91 4.65 10.43 2511 n.d. 
9d H -(CH2)4- CH3 2.77 6.02 6.90 3.22 9.64 >10000 n.d. 
9e H -(CH2)2O(CH2)2- CH3 2.77 6.03 6.92 2.03 8.11 >10000 n.d. 
9f H CH3, Bn CH3 2.77 6.03 6.91 4.32 8.55 2512 n.d. 
20a 




 2.77 5.66 6.33 3.70 9.77 2510 n.d. 
20c 
 -(CH2)2O(CH2)2-  2.77 5.66 6.33 1.08 7.45 >10000 n.d. 
20d 
 -(CH2)2NCH3(CH2)2-  2.77 5.66 6.33 1.03 8.14d >10000 n.d. 
21a 
 CH3, CH3  2.80 5.80 6.66 2.08 8.05 >5000 n.d. 
22a CH3   2.76 6.66 7.50 2.72 8.42 >49000 n.d. 
22b Bn   2.77 6.66 7.49 4.33 7.73 560 -30 
22c H   2.77 6.66 7.49 2.43 9.65 1259 n.d. 
Table 4.1: Calculated physical properties1, geometries, experimental 5-HT7 receptor binding affinities and 
relative potencies of basal adenylate cyclase stimulation of compounds 8b, 8d, 8g-8j, 9b-9f, 20a-20d, 
21a, and 22a-22c. (a) Effect on basal adenylate cyclase activity relative to potencies of 5-CT (+100% at 1.0 
x 10-5 M, full agonist) and methiothepin (-100% at 1.0 x 10-5 M, full inverse agonist). Ligand concentration 
1.0 x 10-4 M. (b) Data derived from literature11,15. (c) 5-HT7 receptor affinity reported in literature: 145 nM6. (d) 
pKa piperazine-NCH3 = 9.61. Not determined abbreviated as n.d. 
 
Introduction of a methyl group at the 2-position of the indole ring of 8g-8j provokes a 
dramatic drop of affinity (ca. 150 fold when 5-MeOT and 8g are compared) and of efficacy 
(compare 8b and 8h). With regard to the findings described in Chapter 3, the current results are in 
agreement with the hypothesis that amino acid residues at the agonist binding site of the 5-HT7 
receptor cause steric hindrance, resulting in low(-er) binding affinities for those compounds that 
have bulky substituents pointing in that particular direction. By comparison of Figure 2.4, Figure 
3.3, and Figure 3.4 it becomes evident that the methyl group at the 2-position of the indole ring of 
8g-8j, and the ethylamine side chain of the THIQs described in Chapter 3, both share this 
characteristic, but to a different extent. In case of 8g-8j, the smaller 2-methyl group experiences 
slight steric hindrance of the interior of the agonist binding site causing decreased affinities. In case 
of THIQs, the larger ethylamine side chain is too big to fit the cavity of the binding site, resulting in 
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no affinity for the 5-HT7 receptor at all. Yet, – presuming that the ligands within this group of 
indoles with a methyl group at the 2-position show comparable efficacy data (efficacy of 8g, 8i-j not 
tested) – these compounds, like 8h, still act as (partial) agonists. 
A shift of the methyl group around the heterocyclic ring of the indole nucleus results in a 
significant decrease of 5-HT7 receptor affinity, similar to that observed for compounds 8g-8j. With 
the methyl group positioned at the indole-NH, there is also a remarkable change in efficacy. Within 
this series, 9b turned out to be an inverse agonist with moderate potency. This result was 
surprising, while the chemical structure and physical properties are very similar to other 
tryptamines that act as (partial) 5-HT7 receptor agonists. In addition, the structure does not comply 
with the prerequisites formulated by the pharmacophore model for 5-HT7 receptor antagonism8 
discussed in Chapter 1, which is in fact primarily based on ligands that show inverse agonism as 
well7,9,14. As a consequence, this finding brings about undiscovered aspects of the pharmacophore 
model. It not only requires further examination of this model, but also raises questions about the 
differences in molecular interactions between agonists and inverse agonists. Unfortunately, 9b was 
the only ligand tested for its effect on adenylate cyclase stimulation within this series. However, 
compounds with larger substituents at the ethylamine side chain lack affinity for the receptor, which 
disqualify them for further screening.  
Within the series of regio isomers of the common tryptamines 20a-20d and 21a, none of 
the ligands showed substantial affinity for the 5-HT7 receptor. In view of the preceding findings and 
the relative similarities of the chemical structures of the THIQs and ligands 20a-20d, these results 
were consistent with the hypothesis that the (bicyclic) core ring structure should be completely flat. 
The 5-membered heterocyclic ring of the indoline-based ligands does not comply with this 
condition and thus no high affinity ligands were to be expected within this series of compounds. 
Additionally, the somewhat smaller distance between the nitrogen of the ethylamine side chain and 
the (hydrogen bond accepting group of the) six-membered aromatic ring compared to the 
geometries of the normal tryptamines may contribute to this lack of affinity as well. However, the 
unmistakable lack of affinity for the 5-HT7 receptor of the flat 21a was astonishing, and may 
suggest a crucial role for a hydrogen bond donating NH-group. Considering the set of ligands that 
was used to develop the initial pharmacophore model for 5-HT7 receptor agonists, this effect was 
estimated to be considerably smaller, where (R)-8-OH-DPAT and 1-naphthylpiperazine showed 
substantial affinity for this receptor subtype. In addition, the slightly shorter distance between this 
nitrogen atom and the (hydrogen bond accepting group of the) six-membered aromatic ring may 
contribute to this lack of affinity. On the other hand, this distance was calculated for 1 to be even 
smaller (5.18 Å) and therefore appears to be less important. However, in this case, it may be 
counterbalanced by the highly restricted conformation of the embedded tryptamine structure, as 
well as by other characteristics of this particular ergoline (e.g. presence of diethyl-amide group). 
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Regarding 22a-22c, we assume that the different orientation of the THP ring of these 
ligands, compared to the rigid structure of the ergoline skeleton of 1, is primarily responsible for the 
low affinity of these compounds for the 5-HT7 receptor. A similar phenomenon could also be seen 
within the series of 6- and 7-substituted 1,2,3,4-tetrahydroisoquinolines with an ethylamine side 
chain at the 2-position, discussed in Chapter 3. Additionally, the inherently larger distance between 
the positively charged nitrogen atom of the THP ring and the (hydrogen bond accepting group of 
the) six-membered aromatic ring may contribute to this observation as well. The moderate affinity 
of 22b with the large benzyl substituent attached to the THP ring appears not to be in line with the 
previous observations as seen within the other series of tryptamines. However, the intrinsic activity 
of this ligand is less surprising, considering the fact that molecular modeling computations 
indicated that 22b fits the hypothesized pharmacophore model for 5-HT7 receptor antagonism8. 
Given the fact that THPI-based ligands generally show higher affinity for the 5-HT1A receptor3 than 
for the receptor subtype of current interest, these findings may contribute to the further exploration 




Summarizing, it can be stated that the number of tryptamines that bind to the 5-HT7 
receptor has been extended, resulting in a more detailed view of the pharmacophore model for 
5-HT7 receptor agonism, and several interesting candidates for computational studies on 3D 
structure-activity relationships, as will be discussed in Chapter 6. Based on the series of 5-
methoxytryptamines, it has become clear that the binding site of the 5-HT7 receptor offers limited 
space for substituents attached to the positively charged nitrogen atom of the ethylamine side 
chain. A methyl group at the 2-position of the indole ring is acceptable without affecting the nature 
of intrinsic activity, but is accompanied by generally lower affinity values. These results are in 
agreement with the conclusions of Chapter 3, stating that the interior of the agonist binding site of 
the 5-HT7 receptor does not allow larger substituents at the 2-position of the indole nucleus nor at 
the nitrogen atom of the ethylamine side chain of THIQ-based ligands. Substitution of the indole-
NH with a methyl group not only causes a significant drop of affinity, but changes the nature of 
these ligands from agonists to inverse agonists as well. This observation, combined with the 
observed lack of affinity of the regio-isomer 21a, suggests an important role for the indole-NH 
group with respect to conformational changes (at the binding site) of the receptor that subsequently 
results in activation of the G-protein. 
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4.6 Experimental Section 
4.6.1 Chemistry 
General remarks 
For general remarks on molecular computations, origin and use of solvents and reactants, as well as characterization 
methods of compounds and determination of their ability to compete for [3H]5-CT binding to cloned rat 5-HT7 receptors 
expressed in HEK-293 cells, the reader is referred to Sections 3.7.1 – 3.7.3. 
 
5-Methoxy-1-methyl-1H-indole (10) 
5-Methoxyindole (5a, 5.00 g, 34.0 mmol) and KO-t-Bu (4.16 g, 37.4 mmol) were suspended in DMF (50 mL) in a 3-
necked flask with reflux condenser under nitrogen. After addition of dimethyl oxalate (4.41 g, 37.4 mmol), the mixture 
was heated to reflux for 4 hr. The suspension was then poured into water (200 mL), and extracted with EtOAc (5 x 50 
mL). The combined organic layers were washed (brine), dried (Na2SO4), and filtered. The volatiles were removed in 
vacuo to yield an off white solid (5.44 g) that was crystallized from diisopropyl ether. 1H-NMR (300 MHz, CDCl3)  (ppm): 
3.83 (d, J = 0.5 Hz, 3H), 3.93 (d, J = 0.7 Hz, 3H), 6.48 (d, J = 3.2Hz, 1H), 6.95 (d, J = 2.4 Hz, 0.5H), 6.99 (dd, Ja = 0.5 
Hz, Jb = 2.0 Hz, 0.5H), 7.09 (d, J = 2.9 Hz, 1H), 7.18 (d, J = 2.4 Hz, 1H), 7.31 (d, J = 2.9 Hz, 1H). 13C-NMR (75 MHz, 
CDCl3)  (ppm): 31.4, 54.4, 98.9, 101.1, 108.3, 110.4, 126.5, 127.8, 138.0, 152.5. IR (KBr, cm-1): 2949, 2904, 2831, 
1619, 1574, 1495, 1418, 1245, 1149, 1099, 1023, 851, 802, 753, 724. MS (EI+): 161 (100%), 146 (100%), 130, 
118(100%), 103, 91, 77, 65, 51. 
 
(5-Methoxy-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride (11) 
Oxalylchloride (2.35 g, 18.6 mmol) was dissolved in ether (75 mL) at 0 ˚C. 5-Methoxy-1-methyl-1H-indole (10, 2.50 g, 
15.5 mmol) was added portionwise. The red precipitate (3.73g) was collected by filtration, dried in vacuo, and used 
without further purification. IR (KBr, cm-1): 3140, 3015, 2955, 2829, 1775, 1650, 1523, 1478, 1370, 1261, 1211, 1129, 
1023, 976, 886, 851, 782, 737. 
 
(5-Methoxy-1H-indol-3-yl)-oxo-acetyl chloride (6a) 
Oxalyl chloride (1.00 g, 8.16 mmol) was dissolved in dry diethyl ether (15 mL) and cooled to 0 ˚C. 5-Methoxyindole (5a, 
1.00 g, 6.80 mmol) was added portionwise. The bright orange precipitate thus formed, was collected by filtration after 30 
min, dried in vacuo (1.45 g) and used without further purification. IR (KBr, cm-1):  3193, 1779, 1617, 1477, 1427, 1267, 
1211, 991, 773, 705, 653. 
 
(5-Methoxy-2-methyl-1H-indol-3-yl)-oxo-acetyl chloride (6b) 
Oxalylchloride (1.39 g, 1.10 mmol) was dissolved in ether (10 mL) at 0 ˚C in a 3-necked flask with dropping funnel under 
nitrogen. 5-Methoxy-2-methyl-1H-indole (5b, 1.61 g, 1.00 mmol), dissolved in ether (10 mL), was added dropwise. After 
addition, the temperature was allowed to rise to rt. The dark-red precipitate was collected by filtration and dried in vacuo 
(2.11 g). This was used for further reactions without purification. IR (KBr, cm-1): 3196, 2837, 1797, 1716, 1602, 1577, 
1485, 1456, 1350, 1271, 1216, 1145, 1106, 1027, 963, 848, 805, 694, 629. 
 
2-(5-Methoxy-1H-indol-3-yl)-N,N-dimethyl-2-oxo-acetamide (7a) 
(5-Methoxy-1H-indol-3-yl)-oxo-acetyl chloride (6a, 0.25 g, 1.05 mmol) was added portionwise to a solution of 
dimethylamine (5 mL, 40% in water) at 0 ˚C. After 30 min CH2Cl2 (50 mL) was added. The layers were separated and the 
inorganic phase was washed with CH2Cl2. The combined organic layers were dried (Na2SO4), filtered, and concentrated 
in vacuo. The residue was crystallized from EtOAc/hexanes to yield 0.23 g of a white solid. 1H-NMR (200 MHz, CD3OD / 
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CDCl3)  (ppm): 2.80 (d, J = 8.8 Hz, 6H), 3.64 (d, 8.8 Hz, 3H), 6.66 (s, 1H), 7.08 (d, J = 8.1 Hz), 7.50 (s, 1H), 7.58 (s, 
1H). IR (KBr, cm-1): 3090, 3038, 2894, 1605, 1518, 1490, 1437, 1265, 1210, 1149, 1030, 808. 
 
[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-dimethyl-amine (8a) 
In a 3-necked flask with cooler, LiAlH4 (0.11 g, 2.89 mmol) was suspended in THF (10 mL) under nitrogen. 2-(5-Methoxy-
1H-indol-3-yl)-N,N-dimethyl-2-oxo-acetamide (7a, 0.20 g, 0.81 mmol), dissolved in THF (10 mL) was added dropwise at 
rt. The suspension was heated to a gentle reflux for 2 hr. After cooling to rt, the excess of LiAlH4 was destroyed by 
careful addition of adequate amounts of water and NaOH (4N). The salts were filtered over Celite, washed well (diethyl 
ether), and the residue was concentrated in vacuo to yield a colorless oil, which was pure 8a according to NMR and GC. 
The free base was converted in the DTTA-salt by addition of 1 equivalent of (+)-DTTA to a solution of the free base in 
i-PrOAc. 1H-NMR (free base, 200 MHz, CDCl3)  (ppm): 2.31 (s, 6H), 2.61 (dd, Ja = 7.3 Hz, Jb = 8.8 Hz, 2H), 2.87 (dd, Ja 
= 7.3 Hz, Jb = 8.8 Hz, 2H), 3.81 (s, 3H), 6.80 (dd, Ja = 2.6 Hz, Jb = 6.2 Hz, 1H), 6.91, (s, 1H), 6.99 (d, J = 2.2 Hz, 1H), 
7.15 (d, J = 8.8 Hz, 1H). 13C-NMR (75 MHz, CDCl3)  (ppm): 21.2, 42.9, 53.5, 57.7, 98.2, 109.4, 109.5, 111.3, 120.0, 
125.3, 129.0, 151.3. IR (free base, neat, cm-1): 3410, 3145, 2930, 2800, 1623, 1580, 1485, 1215, 1171, 1066, 795. MS 
(EI+): 218, 160, 117, 89, 58 (100%). 
 
[2-(5-Methoxy-1-methyl-1H-indol-3-yl)-ethyl]-dimethyl-amine (9a) 
In a 3-necked flask with cooler, [2-(5-methoxy-1H-indol-3-yl)-ethyl]-dimethylamine (8a, 0.18 g, 0.83 mmol) was dissolved 
in DMF under nitrogen. After addition of KO-t-Bu (0.10 g, 0.89 mmol) and dimethyl oxalate (0.10 g, 0.85 mmol), the 
mixture was heated to reflux for 4 hr. The mixture was then allowed to cool to rt, and ammonia (30 mL, 10% in water) 
was added. Extraction with diethyl ether (3 x 15 mL), drying (Na2SO4) of the combined organic layers and subsequent 
evaporation of the volatiles yielded a brown oil (0.17 g), which was purified by chromatography (Silica, gradient 
CH2Cl2/CH3OH). 1H-NMR (300 MHz, CDCl3)  (ppm): 2.30 (s, 6H), 2.57 (dd, Ja = 7.3 Hz, Jb = 8.4 Hz, 2H), 2.82-2.89 (m, 
2H), 3.63 (s, 3H), 3.82 (s, 3H), 6.80 (s, 1H), 6.84 (dd, Ja = 2.2 Hz, Jb = 6.6 Hz, 1H), 7.00 (d, J = 1.8 Hz, 1H), 7.12 (d, J = 
8.8 Hz). 13C-NMR (75 MHz, CDCl3)  (ppm): 21.2, 30.2, 43.0, 53.5, 58.0, 98.4, 107.5, 109.1, 109.7, 124.5, 125.6, 129.9, 
151.1. MS (EI+): 232, 174, 131, 58 (100%). Analysis calc. for: C14H20N2OC2H2O4: C 59.62%, H 6.88%, N 8.69%, O 
24.82%; obsd: C 59.43%, H 6.933%, N 8.83%. 
 
2-(5-Methoxy-1H-indol-3-yl)-2-oxo-N,N-dipropyl-acetamide (7c) 
(5-Methoxy-1H-indol-3-yl)-oxo-acetyl chloride (6a, 0.25 g, 1.05 mmol) was added portionwise to a solution of 
dipropylamine (5 mL, 50% in water). After 30 min CH2Cl2 (50 mL) was added. The layers were separated. The inorganic 
phase was diluted with water (25 mL), and washed with CH2Cl2. The combined organic layers were dried (Na2SO4), 
filtered and concentrated in vacuo to yield a semi solid (0.40 g). Crystallization from EtOAc / hexane yielded pure 7c as a 
colorless solid. 1H-NMR (300 MHz, CDCl3)  (ppm): 0.72 (t, J = 7.3 Hz, 3H), 0.92 (t, J = 7.3 Hz, 3H), 1.49-1.65 (m, 4H), 
3.18 (t, J = 7.7 Hz, 2H), 3.35 (t, J = 7.7 Hz, 2H), 3.81 (s, 3H), 6.80 (dd, Ja = 2.6 Hz, Jb = 6.2 Hz, 1H), 7.15 (d, J = 8.8 Hz, 
1H), 7.47 (d, J = 3.3 Hz, 1H), 7.71 (d, J = 1.8 Hz, 1H), 10.36 (br, 1H). 13C-NMR (75 MHz, CDCl3)  (ppm): 8.6, 8.9, 18.1, 
19.4, 43.7, 47.2, 53.2, 100.6, 110.5, 111.6, 112.0, 123.6, 129.0, 133.0, 148.5, 154.1, 165.9, 183.6. IR (KBr, cm-1): 3147, 
2962, 1632, 1609, 1442, 1271, 1213, 1125, 1086, 1026, 811, 682. 
 
[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-dipropyl-amine (8c) 
In a 3-necked flask with cooler, LiAlH4 (0.18 g, 4.74 mmol) was suspended in THF (20 mL) under nitrogen. 2-(5-methoxy-
1H-indol-3-yl)-2-oxo-N,N-dipropylacetamide (7c, 0.40 g, 1.32 mmol), dissolved in THF (5 mL) was added dropwise. The 
suspension was heated to a gentle reflux for 2 hr. After cooling to rt, the excess of LiAlH4 was destroyed by careful 
addition of adequate amounts of water and NaOH (4N). The salts were filtered over Celite, washed extensively (diethyl 
ether), and the residue was concentrated in vacuo to yield a colorless oil, which was pure 8c according to NMR and GC. 
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1H-NMR (300 MHz, CDCl3)  (ppm): 0.89 (t, J = 7.3 Hz, 6H), 1.47-1.57 (m, 4H), 2.52 (t, J = 7.7 Hz, 4H), 2.76-2.81 (m, 
2H), 2.85-2.90 (m, 2H), 3.83 (s, 3H), 6.82 (dd, Ja = 1.8 Hz, Jb = 7.0 Hz, 1H), 6.91 (s, 1H), 7.02 (d, J = 1.8 Hz, 1H), 7.17 
(d, J = 8.8 Hz, 1H), 8.41 (br, 1H). 13C-NMR (75 MHz, CDCl3)  (ppm): 9.6, 17.7, 20.3, 52.1, 53.4, 53.7, 98.2, 109.4, 
111.6, 120.0, 125.4, 129.0, 151.2. MS (EI+): 274, 174, 160, 114 (100%), 86. 
 
[2-(5-Methoxy-1-methyl-1H-indol-3-yl)-ethyl]-dipropyl-amine (9c) 
In a 3-necked flask with cooler, [2-(5-methoxy-1H-indol-3-yl)-ethyl]-dipropylamine (8c, 0.33 g, 1.20 mmol), KO-t-Bu (0.16 
g, 1.44 mmol), and dimethyl oxalate (0.17 g, 1.44 mmol) were suspended in DMF (10 mL) under nitrogen. The mixture 
was heated to reflux for 2 hr, then allowed to cool to rt, and ammonia (50mL, 10% in water) was added. The water layer 
was extracted with EtOAc (3 x 20 mL), and the combined organic layers were washed (brine), dried (Na2SO4), and 
filtered. The solvent was removed under reduced pressure. This yielded a brown oil (0.30 g) that was purified by 
chromatography (Silica, CH2Cl2 / CH3OH, ratio 20 / 1). 1H-NMR (300 MHz, CDCl3)  (ppm): 0.90 (t, J = 7.3 Hz, 6H), 1.51 
(sx, Ja = 7.3 Hz, Jb = 7.7 Hz, 4H), 2.50 (t, J = 7.7 Hz, 4H), 2.72-2.78 (m, 2H), 2.82-2.88 (m, 2H), 3.66 (s, 3H), 3.84 (s, 
3H), 6.81 (s, 1H), 6.85 (dd, Ja = 2.6 Hz, Jb = 6.2 Hz, 1H), 7.03 (d, J = 2.6 Hz, 1H), 7.13 (d, J = 8.8 Hz). 13C-NMR (75 
MHz, CDCl3)  (ppm): 9.6, 17.9, 20.4, 30.2, 52.5, 53.5, 53.8, 98.5, 107.4, 109.1, 110.2, 124.4, 125.7, 129.9, 151.1. MS 
(EI+): 288, 174, 131, 114 (100%), 86. 
 
1-(5-Methoxy-1H-indol-3-yl)-2-pyrrolidin-1-yl-ethane-1,2-dione (7d) 
(5-Methoxy-1H-indol-3-yl)-oxo-acetyl chloride (6a, 0.50 g, 2.11 mmol) was added portionwise to a solution of pyrrolidine 
(15 mL, 10% in water). CH2Cl2 (50 mL) was added, and stirred vigorously for 30 min at rt. The layers were then 
separated. The inorganic phase was diluted with water (25 mL), and washed with CH2Cl2. The combined organic layers 
were dried (Na2SO4), filtered and concentrated in vacuo to yield a white solid (0.57 g). Crystallization from EtOAc / 
hexane yielded pure 7d as a colorless solid. 1H-NMR (300 MHz, CDCl3)  (ppm): 1.85-1.89 (m, 4H), 3.54 (q, J = 6.2 Hz, 
4H), 3.83 (s, 3H), 6.84 (dd, Ja = 2.6 Hz, Jb = 6.2 Hz, 1H), 7.21 (d, J = 2.6 Hz, 1H), 7.78 (d, J = 2.6 Hz, 1H), 7.90 (d, J = 
3.3 Hz, 1H), 9.89 (br, 1H). 13C-NMR (75 MHz, CDCl3)  (ppm): 22.4, 24.6, 44.3, 45.9, 54.3, 101.8, 111.3, 112.4, 113.0, 




In a 3-necked flask equipped with cooler and dropping funnel, LiAlH4 (0.32 g, 8.42 mmol) was suspended in THF (20 mL) 
under nitrogen. 7d (0.57 g, 2.10 mmol), dissolved in THF (20 mL) was added dropwise. The suspension was heated to a 
gentle reflux for 2 hr. After cooling to rt, the excess of LiAlH4 was destroyed by careful addition of adequate amounts of 
water and NaOH (4N). The salts were filtered over Celite, washed extensively (Ether), and the residue was concentrated 
in vacuo to yield a slightly yellow oil (0.53 g), which was the pure 8d according to NMR and GC. The free base was 
converted in the (+)-DTTA salt by addition of 1 equivalent of (+)-DTTA to a solution of the indole in isopropyl acetate. 1H-
NMR (free base, 200 MHz, CDCl3)  (ppm): 1.80-1.87(m, 4H), 2.62-2.69 (m, 4H), 2.77-2.81 (m, 2H), 2.90-3.00 (m, 2H), 
3.85 (s, 3H), 6.84 (dd, Ja = 2.4 Hz, Jb = 6.4 Hz, 1H), 6.93 (d, J = 2.2 Hz, 1H), 7.06 (d, J = 2.2 Hz, 1H), 7.18 (dd, Ja  = 0.5 
Hz, Jb = 8.3 Hz, 1H), 8.60 (br, 1H). 13C-NMR (50 MHz, CDCl3)  (ppm): 22.0, 23.6, 52.7, 54.4, 55.7, 99.1, 110.4, 112.4, 
121.0, 126.3, 130.0, 152.2. IR (free base, neat, cm-1): 3412, 3140, 2934, 2800, 1624, 1584, 1485, 1215, 1173, 1066, 
795. MS (free base, EI+): 244, 160, 84 (100%). 
 
5-Methoxy-1-methyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole (9d) 
In a 3-necked flask with cooler, 8d (0.40 g, 1.64 mmol), KO-t-Bu (0.28 g, 2.46 mmol), and dimethyl oxalate (0.29 g, 2.46 
mmol) were suspended in DMF (15 mL) under nitrogen. The mixture was heated to a gentle reflux for 2 hr. The reaction 
mixture was allowed to cool to rt, and ammonia (50mL, 10% in water) was added. The water layer was extracted with 
Indole based ligands as potential 5-HT7 receptor agonists Chapter 4 
 99 
EtOAc (4 x 20 mL), and the combined organic layers were washed (brine), dried (Na2SO4), and filtered. The solvent was 
removed under reduced pressure. This yielded a brown oil (0.37 g) that was purified by chromatography (Silica, 
CH2Cl2/CH3OH, ratio 20/1). 1H-NMR (200 MHz, CDCl3)  (ppm): 1.83-1.90 (m, 4H), 2.67-2.74 (m, 4H), 2.78-2.89 (m, 2H), 
2.95-3.05 (m, 2H), 3.69 (s, 3H), 3.86 (s, 3H), 6.87 (dd, Ja = 2.4 Hz, Jb = 6.4 Hz, 1H), 6.86 (s, 1H), 7.06 (d, J = 2.4 Hz, 
1H), 7.16 (d, J = 8.8 Hz, 1H). 13C-NMR (50 MHz, CDCl3)  (ppm): 21.9, 23.1, 31.2, 52.7, 54.5, 55.7, 99.3, 108.5, 110.2, 
110.4, 125.6, 126.5, 130.9, 152.2. MS (EI+): 258, 174, 131, 84 (100%), 70. 
 
1-(5-Methoxy-1H-indol-3-yl)-2-morpholin-4-yl-ethane-1,2-dione (7e) 
(5-Methoxy-1H-indol-3-yl)-oxo-acetyl chloride (6a, 0.40 g, 1.68 mmol) was added portionwise to a two-phase system of 
morpholine (1.46 g, 16.8 mmol) in water (10 mL) and CHCl3 (10 mL). The mixture was stirred vigorously overnight at rt, 
then portioned, and the water layer was washed with CHCl3 (3 x 10 mL). The combined organic layers were dried 
(Na2SO4), filtered, and concentrated in vacuo to yield 0.58 g of a white solid. Pure 7e was obtained by crystallization from 
ethanol. 1H-NMR (200 MHz, CDCl3)  (ppm): 3.51-3.56 (m, 2H), 3.64-3.69 (m, 2H), 3.76 (s, 4H), 3.88 (s, 3H), 6.90 (dd, Ja 
= 2.4 Hz, Jb = 6.4 Hz, 1H), 7.24 (d, J = 7.8 Hz, 1H), 7.75-7.80 (m, 2H), 9.65 (br, 1H). 13C-NMR (50 MHz, CDCl3)  (ppm): 
40.4, 45.1, 54.3, 65.2, 65.5, 101.7, 111.3, 113.4, 124.6, 129.7, 134.1, 155.8, 164.8, 183.7. IR (KBr, cm-1): 3159, 2906, 
2857, 1614, 1517, 1482, 1439, 1270, 1211, 1113, 1032, 966, 918, 808. 
 
5-Methoxy-3-(2-morpholin-4-yl-ethyl)-1H-indole (8e) 
In a 3-necked flask with cooler, LiAlH4 (0.18 g, 4.74 mmol) was suspended in THF (20 mL) under nitrogen. 7e (0.40 g, 
1.39 mmol), suspended in THF (5 mL) was added dropwise. The suspension was heated to a gentle reflux for 3 hr. After 
cooling to rt, the excess of LiAlH4 was destroyed by careful addition of adequate amounts of water and NaOH (4N). The 
salts were filtered over Celite, washed extensively (Ether), and the residue was concentrated in vacuo to yield a slightly 
yellow oil, which was the pure 8e according to NMR and GC. 1H-NMR (300 MHz, CDCl3)  (ppm): 2.52-2.55 (m, 4H), 
2.63-2.68 (m, 2H), 2.87-2.93 (m, 2H), 3.73-3.76 (m, 4H), 3.81 (s, 3H), 6.81 (dd, Ja = 2.6 Hz, Jb = 6.2 Hz, 1H), 6.91 (d, J = 
1.8 Hz, 1H), 7.01 (d, J = 2.2 Hz, 1H), 7.15 (d, J = 8.8 Hz, 1H), 8.43 (br, 1H). 13C-NMR (75 MHz, CDCl3)  (ppm): 20.1, 
51.2, 53.5, 57.1, 64.4, 98.2, 109.5, 111.0, 120.1, 125.3, 129.0, 151.3. MS (EI+): 260, 100 (100%). 
 
5-Methoxy-1-methyl-3-(2-morpholin-4-yl-ethyl)-1H-indole (9e) 
In a 3-necked flask with cooler, 5-methoxy-3-(2-morpholin-4-yl-ethyl)-1H-indole (8e, 0.36 g, 1.39 mmol), KO-t-Bu (0.23 g, 
2.08 mmol), and dimethyl oxalate (0.25 g, 2.08 mmol) were suspended in DMF (15 mL) under nitrogen. The mixture was 
heated to a gentle reflux for 3 hr, then allowed to cool to rt, and quenched with ammonia (50mL, 10% in water). The 
water layer was extracted with EtOAc (3 x 30 mL), and the combined organic layers were washed (brine), dried 
(Na2SO4), and filtered. The solvent was removed under reduced pressure, yielding a brown oil (0.33 g) that crystallized 
upon standing. Recrystallization from EtOAc/hexane yielded the pure 9e as a white solid. 1H-NMR (200 MHz, CDCl3)  
(ppm): 2.53 (d, J = 4.4 Hz, 4H), 2.61-2.66 (m, 2H), 2.86-2.91 (m, 2H), 3.64 (s, 3H), 3.74 (t, J = 4.8 Hz, 4H), 3.82 (3H), 
6.81 (s, 1H), 6.84 (dd, Ja = 2.2 Hz, Jb = 6.6 Hz, 1H), 7.01 (d, J = 2.2 Hz, 1H), 7.12 (d, 8.8 Hz, 1H). 13C-NMR (75 MHz, 
CDCl3)  (ppm): 20.1, 30.2, 51.3, 53.5, 57.3, 64.5, 98.3, 107.5, 109.2, 109.5, 124.5, 125.6, 129.9, 151.2. MS (EI+): 274, 
174, 131, 100 (100%). 
 
N-Benzyl-2-(5-methoxy-1H-indol-3-yl)-N-methyl-2-oxo-acetamide (7f) 
(5-Methoxy-1H-indol-3-yl)-oxo-acetyl chloride (6a, 0.40 g, 1.68 mmol) was added portionwise to a two-phase system of 
benzylmethylamine (0.61g, 5.45 mmol) in water (10 mL) and CHCl3 (10 mL). The mixture was stirred vigorously for 2 hr 
at rt. The organic phase was separated, and the water layer was diluted with water (30 mL) and successively washed 
with CHCl3 (3 x 10 mL). The combined organic layers were washed with HCl (0.25 N, 15 mL), dried (Na2SO4), filtered, 
and concentrated in vacuo to yield 0.51 g of a white solid. 1H-NMR (300 MHz, CDCl3)  (ppm): 2.96-2.96 (m, 3H), 3.86 
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(dd, Ja = 2.2 Hz, Jb = 3.3 Hz, 3H), 4.53 (d, J = 1.8 Hz, 1H), 4.70 (d, J = 1.8 Hz, 1H), 6.85-6.90 (m, 1H), 7.21-7.38 (m, 6H), 
7.73-7.82 (m, 2H), 9.71 (d, J = 22 Hz, 1H). IR (KBr, cm-1): 3134, 3050, 2897, 1613, 1516, 1486, 1441, 1271, 1212, 1154, 
1077, 812, 690. MS (EI+): 322, 174 (100%), 159, 120, 91. 
 
Benzyl-[2-(5-methoxy-1H-indol-3-yl)-ethyl]-methylamine (8f) 
In a 3-necked flask equipped with cooler and dropping funnel, LiAlH4 (0.21 g, 5.53 mmol) was suspended in THF (10 mL) 
under nitrogen. N-Benzyl-2-(5-methoxy-1H-indol-3-yl)-N-methyl-2-oxo-acetamide (7f, 0.45 g, 1.40 mmol), dissolved in 
THF (10 mL),  was added dropwise at rt. The mixture was heated to reflux for 2 hr and successively cooled to rt. The 
excess of LiAlH4 was destroyed by careful addition of adequate amounts of water and NaOH (4N). The salts formed 
were filtered over Celite and washed well (ether). Evaporation of solvents yielded pure 8f as a colorless oil (0.42 g), 
according to TLC and NMR. 1H-NMR (300 MHz, CDCl3)  (ppm): 2.41 (s, 3H), 2.79-2.84 (m, 2H), 3.00-3.06 (m, 2H), 3.67 
(s, 2H), 3.85 (s, 3H), 6.88-6.92 (m, 2H), 7.03 (d, J = 1.8 Hz, 1H), 7.18 (d, J = 8.8 Hz, 1H), 7.30-7-42 (m, 5H), 8.37 (br, 
1H). 13C-NMR (75 MHz, CDCl3)  (ppm): 20.9, 39.9, 53.5, 55.3, 59.9, 98.2, 109.6, 111.4, 120.2, 124.7, 125.5, 125.9, 
126.8, 129.1, 136.4, 151.3. IR (neat, cm-1): 3410, 2942, 1622, 1584, 1486, 1455, 1352, 1213, 1065, 1029, 923, 829, 795, 
739, 699. MS (EI+): 294, 160, 134, 117, 91 (100%). 
 
Benzyl-[2-(5-methoxy-1-methyl-1H-indol-3-yl)-ethyl]-methylamine (9f) 
In a 3-necked flask with cooler, benzyl-[2-(5-methoxy-1H-indol-3-yl)-ethyl]-methylamine (8f, 0.40 g, 1.36 mmol), KO-t-Bu 
(0.23 g, 2.08 mmol), and dimethyl oxalate (0.25 g, 2.08 mmol) were suspended in DMF (15 mL) under nitrogen. The 
mixture was heated to a gentle reflux for 2 hr, then allowed to cool to rt, and quenched with ammonia (50mL, 10% in 
water). The water layer was extracted with EtOAc (3 x 30 mL), and the combined organic layers were washed (brine), 
dried (Na2SO4), and filtered. The solvent was removed under reduced pressure, yielding a brown oil (0.43 g) that 
crystallized upon standing. Recrystallization from EtOAc/hexane yielded the pure 9f as a white solid. 1H-NMR (200 MHz, 
CDCl3)  (ppm): 2.39 (s, 3H), 2.74-2.79 (m, 2H), 2.96-3.02 (m, 2H), 3.63 (s, 2H), 3.67 (s, 3H), 3.85 (s, 3H), 6.83 (s, 1H), 
6.91 (dd, Ja = 2.2 Hz, Jb = 6.6 Hz, 1H), 7.01 (d, J = 2.2 Hz, 1H), 7.17 (d, J = 8.8 Hz, 1H), 7.21-7.40 (m, 5H). IR (neat, cm-
1): 2941, 2832, 2787, 1620, 1578, 1492, 1455, 1422, 1367, 1258, 1225, 1062, 1036, 791, 738, 698. MS (EI+): 308, 174, 
159, 134, 91 (100%). 
 
2-(5-Methoxy-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxo-acetamide (12) 
(5-Methoxy-1-methyl-1H-indol-3-yl)-oxo-acetyl chloride (11, 0.25 g, 1.00 mmol) was added portionwise to a solution of 
dimethylamine (5 mL, 40% in water) at 0 ˚C. After 30 min CH2Cl2 (50 mL) was added. The layers were separated and the 
inorganic phase was washed with CH2Cl2. The combined organic layers were dried (Na2SO4), filtered, and concentrated 
in vacuo. The residue was crystallized from diisopropyl ether to yield 12 as a white solid (0.21 g). 1H-NMR (300 MHz, 
CDCl3)  (ppm): 2.98-3.03 (m, 6H), 3.73 (s, 3H), 3.83 (d, J = 1 Hz, 3H), 6.87-6.92 (m, 1H), 7.17 (dd, Ja = 0.5 Hz, Jb = 8.3 
Hz, 1H), 7.74 (s, 1H), 7.76 (s, 1H). 13C-NMR (75 MHz, CDCl3)  (ppm): 32.4, 32.8, 36.0, 54.3, 102.4, 109.4, 111.2, 112.7, 
125.5, 131.0, 137.8, 155.4, 166.2, 184.0. 
 
2-Dimethylamino-1-(5-methoxy-1-methyl-1H-indol-3-yl)-ethanol (13) 
In a 3-necked flask equipped with cooler and dropping funnel, LiAlH4 (0.38 g, 10.0 mmol) was suspended in THF (10 mL) 
under nitrogen. 2-(5-Methoxy-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxo-acetamide (12, 0.20 g, 0.77 mmol), dissolved 
in THF (5 mL),  was added dropwise at rt. The mixture was heated to reflux overnight, and successively cooled to rt. The 
excess of LiAlH4 was destroyed by careful addition of adequate amounts of water and NaOH (4N). The salts formed 
were filtered over Celite and washed thoroughly (ether). Evaporation of solvents yielded a slightly yellow oil (0.21g), that 
was purified by chromatography (Silica, CH2Cl2/CH3OH gradient). 1H-NMR (300 MHz, CDCl3)  (ppm): 2.34 (s, 6H), 2.44 
(d, J = 2.9 Hz, 0.5H), 2.48 (d, J = 3.3 Hz, 0.5H), 2.75-2.83 (m, 1H), 3.64 (s, 3H), 3.81 (s, 3H), 4.04 (br, 1H), 4.98 (dd, Ja = 
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2.9 Hz, Jb = 7.7 Hz, 1H), 6.82 (d, J = 2.2 Hz, 0.5H), 6.85 (d, J = 2.6 Hz, 0.5H), 6.96 (s, 1H), 7.11-7.14 (m, 2H). 13C-NMR 
(75 MHz, CDCl3)  (ppm): 30.4, 42.9, 53.5, 61.4, 63.5, 95.5, 99.2, 107.6, 109.3, 112.4, 124.3, 130.2, 151.3 
 
2-(5-Methoxy-2-methyl-1H-indol-3-yl)-2-oxo-acetamide (7g) 
To a two-phase system of ammonia (4.00 mL, conc. solution in water) and CHCl3 (5 mL) was added portionwise (5-
methoxy-2-methyl-1H-indol-3-yl)-oxo-acetyl chloride (6b, 0.25 g, 1.00 mmol). The mixture was stirred vigorously at rt for 
4 hr. The layers were separated, and the inorganic phase was diluted with water (25 mL), and extracted with CH2Cl2 (3 x 
10 mL). The organic layers all combined, were dried (Na2SO4), filtered, and concentrated. This yielded a semi-solid (0.18 
g), which was purified by chromatography (Silica, CH2Cl2 / CH3OH). 1H-NMR (300 MHz, CDCl3)  (ppm): 2.98 (s, 3H), 
3.73 (s, 3H), 6.63 (dd, Ja = 2.2 Hz, Jb = 6.6 Hz, 1H), 7.04 (d, J = 6.9 Hz, 1H), 7.40 (br, 1H), 9.80 (br, 1H). 13C-NMR (75 
MHz, CDCl3)  (ppm): 18.2, 54.0, 100.2, 109.5, 109.9, 125.0, 127.7, 153.8, 167.1, 183.7. IR (KBr, cm-1): 3340, 2925, 
1613, 1480, 1437, 1302, 1212, 1134, 1030, 637. MS (EI+): 232, 188 (100%), 173, 145, 117. 
 
2-(5-Methoxy-2-methyl-1H-indol-3-yl)-ethylamine (8g) 
In a 3-necked flask equipped with cooler and dropping funnel, LiAlH4 (0.16 g, 4.21 mmol) was suspended in THF (10 mL) 
under nitrogen. Dissolved in THF (10 mL), 2-(5-methoxy-2-methyl-1H-indol-3-yl)-2-oxo-acetamide (7g, 0.14 g, 0.60 
mmol) was added at rt. The mixture was heated to reflux for 2.5 hr. Excess of LiAlH4 was destroyed by careful addition of 
adequate amounts of water and NaOH (4N). The salts thus formed, were filtered over Celite and washed thoroughly 
(ether). Evaporation of solvents yielded a yellow oil (0.12 g), which was purified by chromatography (Silica, CH2Cl2 / 
CH3OH gradient). 1H-NMR (300 MHz, CDCl3)  (ppm): 2.31 (s, 3H), 2.55-2.65 (m, 2H), 2.85-2.94 (m, 2H), 3.25 (br, 2H), 
3.76 (s, 3H), 6.74 (dd, Ja = 2.6 Hz, Jb = 6.2 Hz, 1H), 6.94 (d, J = 2.2 Hz, 1H), 7.06 (d, J = 8.6 Hz), 8.16 (br, 1H). 13C-NMR 
(75 MHz, CDCl3)  (ppm): 8.9, 24.3, 41.8, 54.5, 100.0, 106.8, 107.6, 108.5, 126.0, 128.2, 130.8, 154.2. MS (EI+): 204, 
174 (100%), 131. 
 
2-(5-Methoxy-2-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxo-acetamide (7h) 
To a two-phase system of dimethylamine (5.00 mL, 40% in water) and CHCl3 (5 mL) was added portionwise: (5-
methoxy-2-methyl-1H-indol-3-yl)-oxo-acetyl chloride (6b, 0.25 g, 1.00 mmol). The mixture was stirred vigorously at rt for 
1 hr. The layers were separated, the inorganic phase was diluted with water (25 mL), and extracted with CH2Cl2 (3 x 10 
mL). The organic layers all combined, were dried (Na2SO4), filtered, and concentrated. This yielded a semi-solid (0.21 g), 
which was crystallized from EtOAc / hexane. 1H-NMR (300 MHz, CDCl3)  (ppm): 2.26 (s, 3H), 2.90 (s, 3H), 3.02 (s, 3H), 
3.72 (s, 3H), 5.30 (br, 2H), 6.62 (dd, Ja = 2.2 Hz, Jb = 6.6 Hz, 1H), 7.02 (d, J = 7.0 Hz, 1H), 7.39 (br, 1H), 9.78 (br, 1H). 
13C-NMR (75 MHz, CDCl3)  (ppm): 19.3, 31.5, 34.6, 53.2, 100.2, 109.9, 125.0, 127.6, 153.8, 167.1, 183.7. IR (KBr, 
cm-1): 3215, 2937, 1613, 1479, 1439, 1302, 1212, 1134, 1030, 637. MS (EI+): 260, 188 (100%), 173, 145, 117, 72. 
 
[2-(5-Methoxy-2-methyl-1H-indol-3-yl)-ethyl]-dimethyl-amine (8h) 
In a 3-necked flask equipped with cooler and dropping funnel, LiAlH4 (0.16 g, 4.21 mmol) was suspended in THF (10 mL) 
under nitrogen. Dissolved in THF (10 mL), 2-(5-methoxy-2-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxo-acetamide (7h, 0.21 
g, 0.81 mmol) was added at rt. The mixture was heated to reflux for 2 hr. The excess of LiAlH4 was destroyed by careful 
addition of adequate amounts of water and NaOH (4N). The salts thus formed, were filtered over Celite and washed 
thoroughly (ether). Evaporation of solvents yielded an yellow oil (0.21 g), which was purified by acid-base separation. 1H-
NMR (300 MHz, CDCl3)  (ppm): 2.25 (s, 3H), 2.33 (s, 6H), 2.44-2.50 (m, 2H), 2.78-2.84 (m, 2H), 3.79 (s, 3H), 6.71 (dd, 
Ja = 2.6 Hz, Jb = 6.2 Hz, 1H), 6.92 (d, J = 2.2 Hz, 1H), 7.05 (d, J = 8.8 Hz), 8.17 (br, 1H). 13C-NMR (75 MHz, CDCl3)  
(ppm): 9.2, 20.3, 42.9, 53.5, 57.7, 98.0, 106.7, 107.7, 108.5, 126.5, 128.0, 129.8, 151.2. MS (EI+): 232, 174, 131, 58 
(100%). 
 




To a 2-phase system of pyrrolidine (10 mL, 15% in water) and CHCl3 (10 mL) was added portionwise (5-methoxy-2-
methyl-1H-indol-3-yl)-oxo-acetyl chloride (6b, 0.25 g, 1.00 mmol). The mixture was stirred vigorously at rt for 0.5 hr. The 
layers were separated, the inorganic phase was diluted with water (30 mL) and extracted with CH2Cl2 (3 x 15 mL). The 
organic layers all combined, were washed with water (10 mL), dried (Na2SO4), filtered, and concentrated. This yielded a 
semi-solid (0.33 g), which was crystallized from EtOAc / hexane. 1H-NMR (300 MHz, CDCl3)  (ppm): 1.78-1.87 (m, 4H), 
2.39 (s, 3H), 3.33 (t, J = 6.2 Hz, 2H), 3.53 (t, J = 6.2 Hz, 2H), 3.72 (s, 3H), 6.64 (dd, Ja = 2.2 Hz, Jb = 6.6 Hz, 1H), 7.01 (d, 
J = 8.8 Hz, 1H), 7.41 (br, 1H), 9.95 (br, 1H). 13C-NMR (75 MHz, CDCl3)  (ppm): 11.4, 20.9, 21.6, 42.6, 50.2, 53.1, 100.1, 
109.6, 109.8, 125.4, 127.9, 145.1, 153.6, 165.3, 184.0. IR (KBr, cm-1): 3178, 2961, 1613, 1484, 1441, 1274, 1213, 1156, 
1107, 1029, 857, 802, 704, 654. MS (EI+): 286, 188 (100%), 173, 145, 117, 55. 
 
5-Methoxy-2-methyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole (8j) 
In a 3-necked flask equipped with cooler and dropping funnel, LiAlH4 (0.20 g, 5.26 mmol) was suspended in THF (15 mL) 
under nitrogen. 1-(5-Methoxy-2-methyl-1H-indol-3-yl)-2-pyrrolidin-1-yl-ethane-1,2-dione (7j, 0.30 g, 1.05 mmol) dissolved 
in THF (10 mL) was added at rt. The mixture was then heated to reflux for 2 hr. Excess of LiAlH4 was destroyed by 
careful addition of adequate amounts of water and NaOH (4N). The salts thus formed, were filtered over Celite and 
washed extensively (ether). Evaporation of solvents yielded a yellow oil (0.31 g), which was purified by acid-base 
separation. 1H-NMR (300 MHz, CDCl3)  (ppm): 1.79 (s, 4H), 2.22 (s, 3H), 2.60-2.66 (m, 6H), 2.83-2.89 (m, 2H), 3.77 (s, 
3H), 6.69 (dd, Ja = 2.2 Hz, Jb = 6.2 Hz, 1H), 6.92 (d, J = 2.2 Hz, 1H), 7.02 (d, J = 8.4 Hz, 1H), 8.29 (br, 1H). 13C-NMR (75 
MHz, CDCl3)  (ppm): 9.1, 21.0, 21.6, 51.7, 53.5, 54.6, 97.9, 106.7, 107.7, 108.5, 126.5, 128.0, 129.8, 151.2. MS (EI+): 
258, 174, 131, 84 (100%), 55. 
 
[2-(5-Methoxy-2-methyl-1H-indol-3-yl)-ethyl]-dipropyl-amine (8i) 
To a two-phase system of dipropylamine (10 mL, 15% in water) and CHCl3 (10 mL) was added portionwise (5-Methoxy-
2-methyl-1H-indol-3-yl)-oxo-acetyl chloride (6b, 0.25 g, 1.00 mmol). The mixture was stirred vigorously at rt for 1 hr. The 
layers were separated, the inorganic phase was diluted with water (30 mL), and extracted with CH2Cl2 (3 x 15 mL). The 
combined organic layers were washed with water (10 mL), dried (Na2SO4), filtered, and concentrated. This yielded a 
semi-solid (0.32 g), which was used in the next step without further purification. (IR, neat, cm-1): 3215, 2948, 1613, 1480, 
1439, 1302, 1275, 1212, 1139, 1110, 1030, 860, 800, 707, 637. The semi-solid was dissolved in THF (10 mL) and added 
to a suspension of LiAlH4 (0.19 g, 5.00 mmol) in THF (10 mL) under a nitrogen. The mixture was heated to a gentle 
reflux for 2 hr. After cooling to rt, the excess of LiAlH4 was carefully decomposed with adequate amounts of water and 
NaOH (4N). The salts were filtered over Celite, washed thoroughly (ether). The amine was then extracted from the 
organic phase with HCl (1N, 3 x 10 mL). The inorganic phase was made alkaline (NaOH, 1N) and extracted with CH2Cl2 
(4 x 20 mL). The combined organic layers were washed (water), dried (Na2SO4), filtered, and concentrated in vacuo to 
yield a colorless oil (0.19 g), which appeared to be pure 8i according to NMR and TLC. 1H-NMR (300 MHz, CDCl3)  
(ppm): 0.89 (t, J = 7.3 Hz, 6H), 1.45-1.55 (m, 4H), 2.28 (s, 3H), 2.48-2.53 (m, 4H), 2.59-2.64 (m, 2H), 2.75-2.81 (m, 2H), 
3.82 (s, 3H), 6.73 (dd, Ja = 1.5 Hz, Jb = 7.3 Hz, 1H), 6.94 (s, 1H), 7.07 (d, J = 8.2 Hz, 1H), 7.73 (br, 1H). 13C-NMR (75 
MHz, CDCl3)  (ppm):9.2, 9.6, 17.8, 19.5, 52.0, 53.4, 53.8, 98.0, 107.4, 107.8, 108.4, 108.7, 126.7, 127.9, 129.6, 151.3. 
IR (neat, cm-1): 3414, 3141, 2934, 2810, 1622, 1580, 1485, 1215, 1172, 1059, 798. MS (free base, EI+): 288, 188, 174, 
114 (100%), 86. 
 
6-Methoxy-1H-indole (16) 
4-Methoxy-1-methyl-2-nitro-benzene (14, 1.00 mL, 7.25 mmol), pyrrolidine (0.7 mL, 8.70 mmol), and dimethylformamide 
dimethyl acetal (1.25 mL, 8.80 mmol) were dissolved in DMF (10 mL). The mixture was heated to 100-110 ˚C overnight. 
The dark purple solution was then quenched with water (100 mL), and extracted with EtOAc (8 x 25 mL). The combined 
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organic layers were washed with brine (2 x 20 mL), dried (Na2SO4), filtered, and concentrated in vacuo to yield the crude 
[2-(4-Methoxy-2-nitro-phenyl)-vinyl]-dimethylamine (15) as a purple oil (1.80 g). Without further purification, the oil was 
dissolved in EtOH (250 mL) and treated with Pd on carbon (75 mg, 10%). The mixture was hydrogenated in a Parr 
apparatus for 4 hr (1 bar H2). The mixture was then filtered over Celite and the solvent was removed. The residue was 
purified by chromatography (silica, CH2Cl2) to yield pure 16 (0.68 g, 4.62 mmol) as colorless crystals (mp 93 ˚C). 1H-
NMR (200 MHz, CDCl3)  (ppm): 3.85 (s, 3H), 6.49 (m, 1H), 6.80 (d, J = 8.5 Hz, 1H), 6.88 (s, 1H), 7.09 (m, 1H), 7.52 (d, 
J = 8.6 Hz, 1H), 8.02 (s, 1H). 13C-NMR (50 MHz, CDCl3)  (ppm): 54.2, 93.0, 101.0, 108.4, 119.7, 121.5. IR (KBr, cm-1): 
3394, 2959, 1628, 1508, 1299, 1161, 1026, 813. MS (EI+): 147, 104 (100%). 
 
6-Methoxy-2,3-dihydro-1H-indole (17) 
6-Methoxy-1H-indole (16, 1.50 g, 10.2 mmol) was dissolved in glacial acetic acid (30 mL). NaCNBH3 (1.9 g, 30.6 mmol) 
was added portionwise, while the temperature did not exceed 20 ˚C. After stirring at rt for 3 hr, the solvent was removed 
under reduced pressure and the residue was treated with NaHCO3 (150 mL, sat.). The water layer was extracted with 
ether (3 x 75 mL), and the combined organic phase was washed with brine (30 mL), dried (Na2SO4) and filtered. 
Evaporation of solvent yielded a colorless oil (1.48 g) that was purified by chromatography (silica, CH2Cl2) to obtain pure 
17. 1H-NMR (200 MHz, CDCl3)  (ppm):2.95 (t, J = 16.6 Hz, 2H), 3.55 (t, J = 16.6 Hz, 2H), 3.75 (s, 3H), 3.88 (br, 1H), 
6.26 (s, 1H), 6.30 (d, J = 2.4 Hz, 1H), 7.00 (d, J = 10.7 Hz, 1H). 13C-NMR (50 MHz, CDCl3)  (ppm): 27.5, 53.9, 95.1, 
102.2, 120.2, 123.3, 151.1, 158.3. IR (neat, cm-1): 3375, 2947, 2847, 1614, 1500, 1286, 1196, 1150, 1030, 830. MS (EI+): 
149 (100 %), 133, 117, 104, 91, 77, 63, 51. 
 
2-Chloro-1-(6-methoxy-2,3-dihydro-indol-1-yl)-ethanone (18) 
A solution of 6-ethoxy-2,3-dihydro-1H-indole (17, 2.20 g, 14.8 mmol) in CH2Cl2 (35 mL) was added dropwise to a mixture 
of 2-chloroacetyl chloride (3.35 g, 29.5 mmol), and K2CO3 (4.50 g, 32.6 mmol) in CH2Cl2 (75 mL). After addition, the 
suspension was stirred at rt for 6 hr. Water (100 mL) was added and the mixture was extracted with CH2Cl2 (3 x 50 mL). 
The combined organic layers were washed with brine (20 mL), dried (Na2SO4), and filtered. Evaporation of the solvent 
yielded an off-white solid (2.95 g). Pure 18 was obtained by crystallization from diisopropyl ether (mp 126 ˚C). 1H-NMR 
(200 MHz, CDCl3)  (ppm): 3.17 (t, J = 16.4 Hz, 2H), 3.80 (s, 3H), 4.16 (s, 2H), 4.17 (t, J = 16.6 Hz, 2H), 6.62 (d, J = 10.5 
Hz, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.90 (s, 1H). 13C-NMR (50 MHz, CDCl3)  (ppm): 25.9, 41.7, 47.2, 54.1, 101.6, 109.5, 
123.2. IR (KBr, cm-1): 2964, 1680, 1497, 1404, 1231, 1028, 842.  
 
2-Dimethylamino-1-(6-methoxy-2,3-dihydro-indol-1-yl)-ethanone (19a) 
Dimethylamine hydrochloride (0.18 g, 2.20 mmol) was added to a suspension of 2-chloro-1-(6-methoxy-2,3-dihydro-
indol-1-yl)-ethanone (18, 0.50 g, 2.20 mmol), and K2CO3 (0.61 g, 4.42 mmol) in acetonitril (25 mL, cat. amount DMF) 
under a nitrogen. The mixture was stirred overnight at 50 ˚C. After filtration, the volatiles were removed in vacuo to yield 
the crude 19a as a semi solid (2.20 g), which was used for reduction without further purification. 1H-NMR (200 MHz, 
CDCl3)  (ppm): 2.35 (s, 3H), 3.05 (t, J = 16.6 Hz, 2H), 3.16 (s, 2H), 3.76 (s, 3H), 4.11 (t, J = 16.8 Hz, 2H), 6.53 (d, J = 
10.5 Hz, 1H), 7.00 (d, J = 8.1 Hz, 1H), 7.89 (s, 1H). 13C-NMR (50 MHz, CDCl3)  (ppm): 25.9, 44.1, 46.7, 54.0, 62.0, 
101.4, 108.5, 123.1. IR (KBr, cm-1): 2933, 2827, 2772, 1654, 1492, 1283, 1157, 1029, 859. MS (EI+): 234, 58 (100%). 
 
[2-(6-Methoxy-2,3-dihydro-indol-1-yl)-ethyl]-dimethylamine (20a) 
LiAlH4 (0.26 g, 6.84 mmol) was suspended in THF (25 mL) under nitrogen and cooled to 0 ˚C. AlCl3 (1.07 g, 8.04 mmol) 
was carefully added and stirred for 15 min. Then, a solution of 2-dimethylamino-1-(6-methoxy-2,3-dihydro-indol-1-yl)-
ethanone (19a, 0.52 g, 2.20 mmol) in THF (10 mL) was added dropwise. The reaction was stirred at rt for 4 hr. Careful 
workup of the reaction by addition of water and NaOH (1N) resulted in the formation of salts, which were removed by 
filtration over Celite. The mother liquor was concentrated in vacuo, and the remainder was partioned between NaHCO3 
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(30 mL, sat.) and CH2Cl2 (50 mL). The organic phase was dried (Na2SO4), filtered, and concentrated in vacuo. 
Purification by chromatography (silica, gradient CH2Cl2 / CH3OH) yielded pure 20a as a colorless oil (0.21 g, 0.95 mmol). 
The free base was converted to its oxalate salt by treatment with oxalic acid dihydrate in ethanol.  1H-NMR (free base, 
200 MHz, CDCl3)  (ppm): 2.26 (s, 6H), 2.49 (t, J = 14.3 Hz, 2H), 2.84 (t, J = 16.5 Hz, 2H), 3.13 (t, J = 14.3 Hz, 2H), 3.35 
(t, J = 16.5 Hz, 2H), 3.71 (s, 3H), 6.03 (s, 1H), 6.11 (d, J = 10.3 Hz, 1H), 6.88 (d, J = 8.1 Hz, 1H). 13C-NMR (50 MHz, 
CDCl3)  (ppm): 25.3, 43.3, 45.1, 51.6, 52.9, 54.3, 92.0, 98.7, 119.8, 121.8, 151.3, 157.6. IR (neat, cm-1): 2942, 2819, 
2767, 1616, 1495, 1281, 1205, 1034, 818. MS (EI+): 220, 162, 58 (100%). Analysis calc. for: C13H20N2OC2H2O4: C 
58.05%, H 7.15%, N 9.03%, O 25.78%; obsd: C 58.21%, H 7.28%, N 9.11%. 
 
[2-(6-Methoxy-indol-1-yl)-ethyl]-dimethylamine (21a) 
[2-(6-Methoxy-2,3-dihydro-indol-1-yl)-ethyl]-dimethylamine  (20a, 0.15 g, 0.68 mmol) and MnO2 (0.30 g, 3.45 mmol) were 
dissolved in acetonitril, and heated to reflux for 4 hr. The dark mixture was then cooled to rt, filtered over Celite and 
concentrated in vacuo to yield a brown oil (0.11 g). The oil was purified by chromatography, to yield 21a as a light brown 
oil (26 mg, 0.12 mmol). The free base was converted in the oxalate by treatment of the free base dissolved in ethanol 
with oxalic acid dihydrate (15 mg, 0.12 mmol). 1H-NMR (free base, 300 MHz, CDCl3)  (ppm): 2.26 (s, 6H), 2.64 (t, J = 
7.3 Hz, 2H), 3.83 (s, 3H), 4.12 (t, J = 7.3 Hz, 2H), 6.37 (d, J = 2.6 Hz, 1H), 6.73 (dd, Ja = 2.2 Hz, Jb = 6.6 Hz, 1H), 6.77 
(s, 1H), 6.98 (d, J = 2.9 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H). 13C-NMR (free base, 75 MHz, CDCl3)  (ppm): 42.2, 43.3, 53.3, 
56.3, 90.5, 98.7, 106.6, 119.0, 120.4, 124.4, 153.7. MS (EI+): 218, 117, 58 (100%). 
 
2-Dipropylamino-1-(6-methoxy-2,3-dihydro-indol-1-yl)-ethanone (19b) 
A solution of dipropylamine (0.65 g, 6.43 mmol) in acetonitril (10 mL) was added dropwise to a suspension of 2-chloro-1-
(6-methoxy-2,3-dihydro-indol-1-yl)-ethanone (18, 0.50 g, 2.22 mmol), and K2CO3 (0.61 g, 4.42 mol) in acetonitril (25 mL, 
cat amount DMF) under nitrogen. The reaction was stirred at 50 ˚C overnight. After filtration, the volatiles were removed 
in vacuo to yield the crude 2-dipropylamino-1-(6-methoxy-2,3-dihydro-indol-1-yl)-ethanone (19b) as a yellow oil (0.51 g), 
which was used for reduction without further purification. 1H-NMR (200 MHz, CDCl3)  (ppm): 0.89 (t, J = 14.7 Hz, 6H), 
1.54 (m, 4H), 2.65 (t, J = 15.1 Hz, 4H), 3.10 (t, J = 8.3 Hz, 2H), 3.43 (s, 2H), 3.80 (s, 3H), 4.21 (t, J = 16.9 Hz, 2H), 6.60 
(d, J = 2.4 Hz, 1H), 7.05 (d, J = 8.1 Hz, 1H), 7.92 (s, 1H). 13C-NMR (50 MHz, CDCl3)  (ppm): 10.3, 18.6, 26.0, 46.9, 
54.1, 54.9, 101.4, 108.8, 123.1. IR (neat, cm-1): 2959, 2870, 1658, 1494, 1284, 1200, 1032, 861. 
 
[2-(6-Methoxy-2,3-dihydro-indol-1-yl)-ethyl]-dipropylamine (20b) 
LiAlH4 (0.20 g, 5.26 mmol) was suspended in THF (20 mL) under nitrogen and cooled to 0 ˚C. H2SO4 (145 L, 96 %) was 
added and stirred for 15 min. Then, a solution of 2-dipropylamino-1-(6-methoxy-2,3-dihydro-indol-1-yl)-ethanone (19b, 
0.50 g, 1.72 mmol) in THF (10 mL) was added dropwise. The reaction was stirred at rt overnight. Careful workup of the 
reaction by addition of water and NaOH (1N) resulted in formation of salts, which were removed by filtration. The mother 
liquor was concentrated in vacuo, and the remainder was partioned between NaHCO3 (30 mL, sat.) and CH2Cl2 (50 mL). 
The organic phase was dried (Na2SO4), filtered, and concentrated in vacuo. Purification by chromatography (silica, 
gradient CH2Cl2/CH3OH) yielded pure 20b as a colorless oil (0.11 g, 0.40 mmol). 1H-NMR (200 MHz, CDCl3)  (ppm): 
0.89 (t, J = 14.6 Hz, 6H), 1.51 (m, 4H), 2.50 (t, J = 15.4 Hz, 4H), 2.17 (t, J = 14.7 Hz, 2H), 2.88 (t, J = 16.4 Hz, 2H), 3.20 
(t, J = 14.7 Hz, 2H), 3.41 (t, J = 16.6 Hz, 2H), 3.78 (s, 3H), 6.07 (s, 1H), 6.15 (d, J = 10.3 Hz, 1H), 6.93 (d, J = 7.8 Hz, 
1H). 13C-NMR (50 MHz, CDCl3)  (ppm): 9.4, 17.6, 25.3, 44.9, 49.0, 51.6, 52.9, 54.1, 91.8, 98.6, 121.8. IR (neat, cm-1): 
2956, 2870, 2829, 1621, 1498, 1285, 1212, 1087, 820. MS (EI+): 276, 114 (100%). 
 
1-(6-Methoxy-2,3-dihydro-indol-1-yl)-2-morpholin-4-yl-ethanone (19c) 
A solution of morpholine (0.40 g, 4.60 mmol) in acetonitril (10 mL) was added dropwise to a suspension of 2-chloro-1-(6-
methoxy-2,3-dihydro-indol-1-yl)-ethanone (18, 0.50 g, 2.22 mmol), and K2CO3 (0.61 g, 4.42 mol) in acetonitril (25 mL, cat 
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amount DMF) under nitrogen. The reaction was stirred at 50 ˚C overnight. After filtration, the volatiles were removed in 
vacuo to yield the crude 1-(6-methoxy-2,3-dihydro-indol-1-yl)-2-morpholin-4-yl-ethanone (19c) as a slightly yellow solid 
(0.58 g). Crystallization from EtOAc/hexane yielded the pure compound (mp 103 ˚C). 1H-NMR (200 MHz, CDCl3)  
(ppm): 2.67 (d, J = 2.7 Hz, 4H), 3.06 (t, J = 16.6 Hz, 2H), 3.30 (s, 2H), 3.71 (s, 3H), 3.72 (d, J = 9.3 Hz, 4H), 6.52 (d, J = 
10.5 Hz, 1H), 6.99 (d, J = 8.3 Hz, 1H), 7.79 (s, 1H). 13C-NMR (50 MHz, CDCl3)  (ppm): 25.8, 46.6, 52.0, 53.9, 60.1, 
64.9, 101.5, 108.9, 123.2. IR (KBr, cm-1): 3519, 2947, 2867, 1655, 1456, 1306, 1109, 857. MS (EI+): 276, 100 (100%). 
 
6-Methoxy-1-(2-morpholin-4-yl-ethyl)-2,3-dihydro-1H-indole (20c) 
LiAlH4 (0.07 g, 1.84 mmol) was suspended in THF (10 mL) under nitrogen and cooled on ice to 0 ˚C. H2SO4 (50 L, 96 
%) was added and stirred for 15 min. Then, a solution of 1-(6-methoxy-2,3-dihydro-indol-1-yl)-2-morpholin-4-yl-ethanone 
(19c, 0.25 g, 0.91 mmol) in THF (5 mL) was added dropwise. The reaction was stirred at rt overnight. Careful workup of 
the reaction by addition of water and NaOH (1N) resulted in formation of salts, which were removed by filtration over 
Celite. The mother liquor was concentrated in vacuo, and the remainder was partioned between NaHCO3 (30 mL, sat.) 
and CH2Cl2 (50 mL). The organic phase was dried (Na2SO4), filtered, and concentrated in vacuo. Purification by 
chromatography (silica, gradient CH2Cl2 / CH3OH) yielded pure 20c as a colorless oil (0.10 g, 0.38 mmol). 1H-NMR (200 
MHz, CDCl3)  (ppm): 2.51 (t, J = 8.4 Hz, 4H), 2.57 (t, J = 14.3 Hz, 2H), 2.84 (t, J = 16.1 Hz, 2H), 3.19 (t, J = 14.3 Hz, 
2H), 3.37 (t, J = 16.5 Hz, 2H), 3.69 (t, J = 10.6 Hz, 4H), 3.71 (s, 3H), 6.02 (s, 1H), 6.11 (d, J = 8.1 Hz, 1H), 6.88 (d, J = 
7.7 Hz, 1H). 13C-NMR (50 MHz, CDCl3)  (ppm): 25.3, 44.1, 51.5, 51.7, 52.9, 53.7, 64.3, 91.9, 98.8, 121.9. IR (neat, cm-
1): 3372, 2948, 2847, 1617, 1498, 1286, 1207, 1116, 1034, 820. MS (EI+): 262, 162 (100%). 
 
1-(6-Methoxy-2,3-dihydro-indol-1-yl)-2-(4-methyl-piperazin-1-yl)-ethanone (19d) 
A solution of N-methylpiperazine (0.28 g, 2.80 mmol) in acetonitril (10 mL) was added dropwise to a suspension of 2-
chloro-1-(6-methoxy-2,3-dihydro-indol-1-yl)-ethanone (18, 0.50 g, 2.22 mmol), and K2CO3 (0.61 g, 4.42 mol) in acetonitril 
(25 mL, cat amount DMF) under nitrogen. The reaction was stirred at 50 ˚C overnight. After filtration, the volatiles were 
removed in vacuo to yield the crude 1-(6-methoxy-2,3-dihydro-indol-1-yl)-2-(4-methyl-piperazin-1-yl)-ethanone (19d) as a 
slightly yellow semi solid (0.64 g), that contained only minor contaminants according to NMR and GC. The sample was 
used for further synthesis without purification. 1H-NMR (200 MHz, CDCl3)  (ppm): 2.26 (s, 3H), 2.54 (d, J = 35.9 Hz, 
8H), 3.05 (t, J = 16.5 Hz, 2H), 3.18 (s, 2H), 3.73 (s, 3H), 4.10 (t, J = 16.8 Hz, 2H), 6.51 (d, J = 10.3 Hz, 1H), 6.99 (d, J = 
8.4 Hz, 1H), 7.87 (s, 1H). 13C-NMR (50 MHz, CDCl3)  (ppm): 25.0, 43.4, 45.8, 50.8, 52.4, 53.0, 59.9, 100.3, 107.9, 
120.3, 122.1, 156.9, 165.2. IR (neat, cm-1): 2932, 2800, 1664, 1454, 1302, 1162, 1010, 827. MS (EI+): 289, 113 (100%). 
 
6-Methoxy-1-[2-(4-methyl-piperazin-1-yl)-ethyl]-2,3-dihydro-1H-indole (20d) 
LiAlH4 (0.25 g, 6.58 mmol) was suspended in THF (25 mL) under nitrogen and cooled on ice to 0 ˚C. H2SO4 (170L, 96 
%) was added and stirred for 15 min. Then, a solution of 1-(6-methoxy-2,3-dihydro-indol-1-yl)-2-(4-methyl-piperazin-1-yl)-
ethanone (19d, 0.64 g, 2.21 mmol) in THF (10 mL) was added dropwise. The reaction was stirred at rt for 6 hr. Careful 
workup of the reaction by addition of water and NaOH (1N) resulted in formation of salts, which were removed by 
filtration over Celite. The mother liquor was concentrated in vacuo, and the remainder was partioned between NaHCO3 
(30 mL, sat.) and CH2Cl2 (50 mL). The organic phase was dried (Na2SO4), filtered, and concentrated in vacuo. 
Purification by chromatography (silica, gradient CH2Cl2/CH3OH) yielded pure 20d as a colorless oil (0.05 g, 0.18 mmol). 
The product was converted in the (+)-DTTA salt by treatment of the free base with 1 equivalent of (+)-DTTA. 1H-NMR 
(free base, 200 MHz, CDCl3)  (ppm): 2.35 (s, 3H), 2.62 (m, 10 H), 2.88 (t, J = 16.4 Hz, 2H), 3.21 (t, J = 14.2 Hz, 2H), 
3.40 (t, J = 16.6 Hz, 2H), 3.75 (s, 3H), 6.07 (s, 1H), 6.16 (d, J = 10.3 Hz, 1H), 6.13 (d, J = 8.1 Hz, 1H). 13C-NMR (free 
base, 50 MHz, CDCl3)  (ppm): 26.3, 44.1, 45.4, 51.5, 52.6, 53.3, 53.9, 54.0, 93.0, 99.8, 122.7. IR ((+)-DTTA salt, KBr, 
cm-1): 2954, 2841, 1719, 1615, 1497, 1349, 1266, 1107, 752. MS (free base, EI+): 275, 113 (100%). 
 




In a 3-necked flask with cooler, 5-methoxyindole (5a, 0.50 g, 3.40 mmol) was dissolved in CH3OH (5 mL) under nitrogen. 
N-methyl-4-piperidone (1.15 g, 10.2 mmol) and NaOCH3 (5 mL, 30 % solution in CH3OH) were added, and the mixture 
was heated to reflux for 3 hr. The reaction was allowed to cool to rt. The volatiles were removed under reduced pressure, 
and the residue was partioned between water and CH2Cl2. Extraction of the water layer with CH2Cl2 (3 x 15 mL) and 
drying of the combined organic layers (Na2SO4) was followed by filtration and evaporation of the solvent. This yielded an 
orange semi-solid (0.80 g) that was recrystallized from EtOAc. 1H-NMR (300 MHz, CDCl3)  (ppm): 2.24 (s, 3H), 2.46-
2.48 (m, 2H), 2.54-2.58 (m, 2H), 3.03 (d, J = 2.9 Hz, 2H), 3.69 (s, 3H), 5.94 (s, 1H), 6.67 (dd, Ja = 2.2 Hz, Jb = 6.6 Hz, 
1H), 7.01 (s, 1H), 7.10 (d, J = 9.2 Hz, 1H), 7.14 (d, J = 2.2 Hz, 1H). 13C-NMR (75 MHz, CDCl3)  (ppm): 25.9, 42.7, 49.5, 
52.0, 53.4, 77.7, 100.2, 109.0, 109.5, 114.4, 120.1, 122.6, 127.5, 130.0, 136.0, 151.8. IR (KBr, cm-1): 3032, 2854, 2794, 
1650, 1615, 1477, 1448, 1379, 1260, 1210, 1125, 1034, 961, 882, 807, 736. MS (EI+): 242, 227, 198, 84. 
 
3-(1-Benzyl-1,2,3,6-tetrahydro-pyridin-4-yl)-5-methoxy-1H-indole (22b) 
In a 3-necked flask with cooler, 5-methoxyindole (5a, 0.50 g, 3.40 mmol) was dissolved in CH3OH (5 mL) under nitrogen. 
N-benzyl-4-piperidone (0.96 g, 5.08 mmol) and NaOCH3 (5 mL, 30 % solution in CH3OH) were added, and the mixture 
was heated to reflux for 4 hr. The reaction was allowed to cool to rt. The precipitate that was formed, was collected by 
filtration (0.90 g), and dried in vacuo. Crystallization from EtOAc yielded pure 22b as a white solid. 1H-NMR (300 MHz, 
CDCl3)  (ppm): 2.53 (d, J = 1.5 Hz, 2H), 2.68-2.72 (m, 2H), 3.20 (dd, Ja = 2.6 Hz, Jb = 2.9 Hz, 2H), 3.62 (s, 2H), 3.80 (s, 
3H), 6.07-6.09 (m, 1H), 6.79-6.83 (m, 1H), 7.07 (d, J = 2.6 Hz, 1H), 7.17-7.38 (m, 7H), 8.00 (br, 1H). 13C-NMR (75 MHz, 
CDCl3)  (ppm): 26.7, 47.6, 50.8, 53.5, 60.5, 100.5, 109.3, 109.7, 116.4, 119.5, 123.1, 124.6, 125.8, 126.8, 127.4, 151.9. 
IR (KBr, cm-1): 3032, 2925, 2854, 2794, 1650, 1614, 1601, 1479, 1447, 1380, 1260, 1211, 1125, 1034, 962, 880, 807, 
736. MS (EI+): 318, 227, 198, 160, 128, 91 (100%). Analysis calc. for: C21H22N2O: C 79.21%, H 6.96%, N 8.80%, O 
5.02%; obsd: C 79.11%, H 7.05%, N 9.01%. 
 
4-(6-Methoxy-3H-inden-1-yl)-1,2,3,6-tetrahydro-pyridine (22c) 
3-(1-Benzyl-1,2,3,6-tetrahydro-pyridin-4-yl)-5-methoxy-1H-indole (22b, 0.40 g, 1.26 mmol), dissolved in ethanol (25 mL), 
was reacted with Pd/C (0.10 g, 10%) under a hydrogen atmosphere (1 atm) in a Parr shaker apparatus for 2 hr at rt. The 
reaction mixture was filtered over Celite and concentrated in vacuo to yield 22c as a slightly yellow oil (0.27 g, 1.25 
mmol). 1H-NMR (300 MHz, CDCl3)  (ppm): 2.38-2.46 (m, 2H), 2.52-2.56 (m, 2H), 3.07 (d, J = 2.9 Hz, 2H), 3.26 (br, 1H), 
3.69 (s, 3H), 5.96 (s, 1H), 6.68 (dd, Ja = 2.2 Hz, Jb = 6.7 Hz, 1H), 7.03 (s, 1H), 7.10 (d, J = 9.2 Hz, 1H), 7.16 (d, J = 2.2 
Hz, 1H). 13C-NMR (75 MHz, CDCl3)  (ppm): 40.6, 50.5, 52.0, 53.6, 74.7, 100.2, 108.1, 110.5, 114.2, 121.1, 123.8, 
127.5, 130.2, 138.0, 152.0. IR (KBr, cm-1): 3254, 3028, 2824, 2798, 1649, 1617, 1477, 1448, 1378, 1261, 1210, 1124, 
1034, 961, 882. MS (EI+): 228, 198, 70. 
 
4.6.2 Pharmacology 
5-HT7 Adenylate Cyclase Assay 
Effects on adenylate cyclase activity were measured according to previously published methods12.  HEK-293 cells 
expressing the rat 5-HT7 were grown in Dulbecco's modified Eagle's media (DMEM) containing fetal bovine serum 
(10%), G418 (Geneticin, 400 µg), and glutamine (2 mM) until flasks were confluent.  Cells from confluent flasks were 
harvested by replacing the media with phosphate buffered saline (PBS) containing EDTA (5 mM, pH = 7.4).  Cells were 
homogenized in HEPES buffer (5 mM) containing EGTA (1 mM, pH = 7.4) using a hand-held glass-teflon homogenizer.  
The homogenate was centrifuged in 35,000 g for ten minutes.  The cell pellet was resuspended in HEPES buffer (100 
mM) containing EGTA (1 mM, pH = 7.4). Membranes (30-40 µg protein) were incubated at 37 °C in a reaction medium 
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containing Hepes (100 mM, pH = 7.4), MgCl2 (5.0 mM), ATP (0.5 mM), cAMP (1.0 mM), IBMX (0.5 mM), 
phosphocreatine (10 mM), creatine phosphokinase (0.31 mg/mL), GTP (100 µM), µ-[33P]ATP (1 µCi) per tube and test 
drugs (final volume of 100 µl).  Incubations were terminated after 15 minutes by adding sodium dodecyl sulfate (2%).  
After separation of [33P]cAMP from [33P]ATP as described by Salomon12, [33P]cAMP levels were determined by liquid 
scintillation counting, with the results expressed as picomoles per minute per milligram of protein.  EC50 and IC50 values 
were calculated by linear regression analysis of the concentration-response curves. Efficacy values were calculated as 
the maximal effect of an agonist in terms of the maximal effect produced by a known agonist such as 5-HT.  Apparent Ki 
values for antagonists were calculated as follows: Ki = IC50/(1 + (C/EC50)), where C is the concentration of the agonist 
used in the experiment and EC50 is the EC50 for the agonist. 
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